Literature DB >> 21911602

Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells.

Meriem Hasmim1, Muhammad Zaeem Noman, Jessica Lauriol, Houssem Benlalam, Aude Mallavialle, Filippo Rosselli, Fathia Mami-Chouaib, Catherine Alcaide-Loridan, Salem Chouaib.   

Abstract

Hypoxia is a major feature of the solid tumor microenvironment and is known to be associated with tumor progression and poor clinical outcome. Recently, we reported that hypoxia protects human non-small cell lung tumor cells from specific lysis by stabilizing hypoxia-inducible factor-1α and inducing STAT3 phosphorylation. In this study, we show that NANOG, a transcription factor associated with stem cell self renewal, is a new mediator of hypoxia-induced resistance to specific lysis. Our data indicate that under hypoxic conditions, NANOG is induced at both transcriptional and translational levels. Knockdown of the NANOG gene in hypoxic tumor cells is able to significantly attenuate hypoxia-induced tumor resistance to CTL-dependent killing. Such knockdown correlates with an increase of target cell death and an inhibition of hypoxia-induced delay of DNA replication in these cells. Interestingly, NANOG depletion results in inhibition of STAT3 phosphorylation and nuclear translocation. To our knowledge, this study is the first to show that hypoxia-induced NANOG plays a critical role in tumor cell response to hypoxia and promotes tumor cell resistance to Ag-specific lysis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911602     DOI: 10.4049/jimmunol.1101011

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Yosra Messai; Stéphane Terry; Claudine Kieda; Bassam Janji; Salem Chouaib
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

Review 2.  Concise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding Questions.

Authors:  Collene R Jeter; Tao Yang; Junchen Wang; Hsueh-Ping Chao; Dean G Tang
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

3.  Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes.

Authors:  Young-Ho Lee; Hyun Cheol Bae; Kyung Hee Noh; Kwon-Ho Song; Sang-kyu Ye; Chih-Ping Mao; Kyung-Mi Lee; T-C Wu; Tae Woo Kim
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

Review 4.  Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.

Authors:  Nicole Colwell; Mioara Larion; Amber J Giles; Ashlee N Seldomridge; Saman Sizdahkhani; Mark R Gilbert; Deric M Park
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

Review 5.  Regulation of NANOG in cancer cells.

Authors:  Shuai Gong; Qiuhui Li; Collene R Jeter; Qingxia Fan; Dean G Tang; Bigang Liu
Journal:  Mol Carcinog       Date:  2015-05-27       Impact factor: 4.784

Review 6.  The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells.

Authors:  Natalia Gawlik-Rzemieniewska; Ilona Bednarek
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

Review 7.  Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Authors:  Mariacarmela Santarpia; María González-Cao; Santiago Viteri; Niki Karachaliou; Giuseppe Altavilla; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2015-12

Review 8.  Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.

Authors:  Vinit Kumar; Dmitry I Gabrilovich
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

Review 9.  Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.

Authors:  Guangna Liu; Wei Rui; Xueqiang Zhao; Xin Lin
Journal:  Cell Mol Immunol       Date:  2021-03-30       Impact factor: 11.530

10.  Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

Authors:  Shujing Shi; Rui Wang; Yitian Chen; Haizhu Song; Longbang Chen; Guichun Huang
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.